Mineralys Therapeutics stock edges lower amid oversold conditions and consolidation risk in $21

Traders Union
All News
Companies
Mineralys Therapeutics down 1.46% today

Highlights

MLYS trades well below key moving averages, signaling sustained bearish momentum across short-, medium-, and long-term timeframes.
All major momentum indicators are bearish or oversold, indicating heavy selling pressure and limited immediate upside potential.
Baseline expectation is for MLYS to consolidate between $21 and $25 next week, with risks skewed toward a further decline if support breaks.

Sustained bearish pressure as price lags key averages and meets clustered resistance

MLYS is trading at $23.35, which is well below the MA-20 ($28.39), MA-50 ($27.99), and MA-200 ($32.76), reflecting pronounced short-, medium-, and long-term bearish pressure. The Ichimoku Kijun on D1 sits at $27.71, marking an immediate resistance above the current price. Near-term support appears at the HMA ($23.84) and the weekly MA-100 EMA ($23.60), while resistance clusters at the MA-20 ($28.39) and the Ichimoku Kijun ($27.71) as well as the MA-50 ($27.99), serving as key resistance levels.

Oversold signals deepen as intraday sellers persist after failed rally

Momentum indicators on D1 remain weak: MACD is neutral-to-bearish, while ADX at 15.10 signals a lack of strong trend direction. RSI (33.17), Stoch RSI (0.00), and CCI (–155.64) highlight clear oversold conditions, suggesting downside may be exhausted. However, BBP at –2.70 and its “Oversold” classification confirm that sellers still dominate intraday, reinforcing the persistent bearish undertone. The Awesome Oscillator also points to strong sell pressure, which is consistent with the prevailing trend. MLYS has fallen $0.34 (0.97%) from last week’s close of $23.69, placing the current price at the bottom of the weekly range as volatility stands at a notably high 31.36%. This steady decline from the week’s high ($30.70) reflects continued pressure after a failed rally.

High probability of further downside as bearish momentum dominates short-term outlook

Looking ahead, the expected price range for the next week is $21.00–$25.00, adjusted for recent volatility and anchoring current levels between the 52-week low ($12.59) and high ($47.65). The probability of a further price decrease is very high (more than 80%), as all W1 momentum indicators—RSI (40.81), MACD (–0.97), ADX (15.28), and MA-50 W1—signal a bearish bias. The opposite, that is, an advance from these levels, is much less likely. The baseline scenario is for MLYS to consolidate within a sideways corridor around $23 with broad $21–$25 swing risk. If sellers push below $23, a short-lived extension toward $21 is likely, while a bullish reversal would require regaining the $27–$28 resistance zone to shift the tone. The price remains far above its annual low but well below mid-year highs, underscoring an overall recovery that has reversed sharply in recent sessions.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Mineralys Therapeutics planned to release its third-quarter financial results and provide a detailed update to investors. With attention now shifting to post-earnings developments, it will be important for market participants to monitor $MLYS for any emerging trends in trading activity or company guidance.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.